PDCD1 and neoplasm: Combination therapy consisting of an antagonist of miR-146a and anti–PD-1 antibody resulted in enhanced survival of tested mice over anti–PD-1 treatment alone and could be a novel strategy improving anti-tumor response compared to ICI therapy [137].